MYO 201
Alternative Names: AAVrh-74-MHCK7-DYSF; AAVrh.74.MHCK7.DYSF; MYO201; SRP-6004Latest Information Update: 24 May 2024
Price :
$50 *
At a glance
- Originator Nationwide Children's Hospital
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Limb girdle muscular dystrophy type 2B
Most Recent Events
- 27 Mar 2024 Pharmacodynamics data from a preclinical trial in Limb-girdle muscular dystrophy type 2B presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2024)
- 22 May 2023 Phase-I clinical trials in Limb girdle muscular dystrophies type 2B (LGMD2B) in USA (IV) (NCT05906251)
- 22 Mar 2022 MYO 201 is still in phase I trials for Limb girdle muscular dystrophies type 2B in USA (IM)